The African-American heart failure trial: Background, rationale and significance

Journal of the National Medical Association

Volumn 94, Issue 9, 2002, Pages 762-769

  Taylor, Anne L ^a   Cohn, Jay N ^a   Worcel, Manuel ^a   Franciosa, Joseph A ^a  

^a NONE

Author keywords

Heart failure; Hydralazine; Isosorbide dinitrate; Vasodilators

Indexed keywords

CARDIOVASCULAR AGENT; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE HYDRALAZINE COMBINATION; ISOSORBIDE-HYDRALAZINE COMBINATION;

AFRICAN AMERICAN; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; ETHNOLOGY; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

AFRICAN AMERICANS; CARDIOVASCULAR AGENTS; DRUG COMBINATIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; RESEARCH DESIGN;

EID: 0036729830     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:1392-1393.
2. Taylor HA. Capacity building for research in minority health. Am J Med Sci. 2001;322:241-242.
3. Hassaballa H, Gorelick PB, West CP, Hansen MD, Adams HP. Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST). Neurology. 2001;57:691-697.
4. Yancy CW. Curr Cardiol Rep. 2001;3:191-197.
5. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-69.
6. Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36: 2284-2286.
7. Pearson TA. Capacity for research in minority health: the need for infrastructure plus will. Am J Med Sci. 2001;322:243-247.
8. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Cardiac Failure. 1999;5:178-187.
9. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
10. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, and Packer M for the US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
11. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
12. Becker DM, Tuggle MB, Prentice MF. Building a gateway to promote cardiovascular health research in African American communities: lessons and findings from the field. Am J Med Sci. 2001;322:276-281.
13. Epstein AM, Ayanian JZ. Racial disparities in medical care. N Engl J Med. 2001;344:1471-1473.
14. Alexander M, Grumbach K, Remy L, Rowell R, Massie BM. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J. 1999; 137:919-927.
15. Philbin EF, Dec GW, Jenkins PL, DiSalvo TG. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87:1367-1371.
16. Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol. 1998;82:76-81.
17. Fouad MN, Partridge E, Green BL, Kohler C, Wynn T, Nagy S, Churchill S. Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community. Ann Epidemiol. 2000;10(8 Suppl):S35-S40.
18. Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African American participation in AIDS research. J Acquir Immune Defic Syndr. 2000;24:275-284.
19. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW. ACC/ AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
20. Wood AJJ. Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med. 2001; 344:1393-1395.
21. Loscalzo J, Welch G. Nitric oxide and the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87-104.
22. Perregaux D, Chaudhuri A, Rao S, Aircn A, Wilson M, Sung BH, Dandona P. Brachial vascular reactivity in blacks. Response to mental stress in the forearm circulation. Hypertension. 2000;36:866-871.
23. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998;31:1235-1239.
24. Kelsey RM, Alpert BS, Patterson SM, Barnard M. Racial differences in hemodynamic responses to environmental thermal stress among adolescents. Circulation. 2000;101:2284-2289.
25. Munzel T, Kurz S, Rajagopalan S. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest. 1996;98:1465-1470.
26. Bauer J, Fung H. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35-39.
27. Cohn JN, Archibald DG, Phil M, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med. 1986; 314:1547-1552.
28. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
29. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel W, for the A-HeFT Investigators. African American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Cardiac Failure. 2002;8:128-135.
30. Rector TS, Cohn JN, with the Pimobendan Multicenter Research Group. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124:1017-1025.